Brief: Study Shows Biocept's Technology Improves Rare Cancer Mutations Detection Assays

Biocept

09/11/2021 13:27

Nov 9 (Reuters) - Biocept Inc  BIOC.O :
    * STUDY SHOWS BIOCEPT’S SWITCH-BLOCKER TECHNOLOGY ENHANCES
PERFORMANCE OF CONVENTIONAL PCR-BASED LIQUID BIOPSY ASSAYS IN
DETECTING RARE CANCER MUTATIONS

Source text for Eikon:  ID:nBw8MZZX4a 
Further company coverage:  BIOC.O 

 ((Reuters.Briefs@thomsonreuters.com;))